MRSN — Mersana Therapeutics, Inc. Common Stock

XNAS · Healthcare · Biotechnology

Price $9.30

Market Cap $46.4M

P/E —

52W Range $5.21 – $70.75

About Mersana Therapeutics, Inc. Common Stock

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.